Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers
Condition(s):Locally Advanced Adrenal Gland Pheochromocytoma; Locally Advanced Paraganglioma; Metastatic Adrenal Gland Pheochromocytoma; Metastatic Paraganglioma; Metastatic Parathyroid Gland Carcinoma; Pituitary Gland Carcinoma; Somatostatin Receptor Positive; Stage III Thyroid Gland Medullary Carcinoma AJCC v8; Stage IV Thyroid Gland Medullary Carcinoma AJCC v8; Stage IVA Thyroid Gland Medullary Carcinoma AJCC v8; Stage IVB Thyroid Gland Medullary Carcinoma AJCC v8; Stage IVC Thyroid Gland Medullary Carcinoma AJCC v8; Unresectable Adrenal Gland Pheochromocytoma; Unresectable ParagangliomaLast Updated:September 7, 2020Withdrawn